ERBB2 and breast carcinoma: Song et al clarified that the significantly up-regulated NCAPG confered trastuzumab resistance to HER2-positive breast cancer by activating the SRC/STAT3 signal axis, which illustrated that NCAPG also played a non-negligible role in tumor resistance.